NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High-Quality Cancer Care

Authors:
Terrell Johnson National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

Search for other papers by Terrell Johnson in
Current site
Google Scholar
PubMed Close
 MPA
,
Michelle McMurry-Heath Biotechnology Innovation Organization, Washington, DC;

Search for other papers by Michelle McMurry-Heath in
Current site
Google Scholar
PubMed Close
 MD
,
Ted Okon Community Oncology Alliance, Washington, DC; and

Search for other papers by Ted Okon in
Current site
Google Scholar
PubMed Close
 MBA
,
David Rubin Memorial Sloan Kettering Cancer Center, New York, New York.

Search for other papers by David Rubin in
Current site
Google Scholar
PubMed Close
, and
Robert W. Carlson National Comprehensive Cancer Network, Plymouth Meeting, Pennsylvania;

Search for other papers by Robert W. Carlson in
Current site
Google Scholar
PubMed Close
 MD
Volume/Issue:
Volume 19: Issue 9
Online Publication Date:
20 Sep 2021
DOI:
https://doi.org/10.6004/jnccn.2021.7084
Restricted access

The cost of delivering high-quality healthcare in America now consumes 17.7% of the nation’s gross domestic product according to Centers for Medicare & Medicaid Services National Health Expenditure Data. With costs threatening to disrupt accessible and equitable care for patients, policymakers are reassessing all matters and functions of the healthcare system to excise waste, redundancies, and costly services. To explore this subjects’ impact on oncology, NCCN hosted the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care. This virtual summit featured multidisciplinary panel discussions and keynote addresses. Seeking to address barriers to low-cost, high-quality cancer care, panelists and keynotes presented innovative policy solutions to sustain high-quality oncologic care at lower costs to the health system. This article encapsulates the discussions held during the summit and expounds upon salient points where appropriate.

Submitted February 19, 2021; final revision received July 26, 2021; accepted for publication July 27, 2021.

Disclosures: The authors have disclosed that they have not received any financial considerations from any person or organization to support the preparation, analysis, results, or discussion of this article.

Correspondence: Terrell Johnson, MPA, National Comprehensive Cancer Network, 3025 Chemical Drive, Suite 100, Plymouth Meeting, PA 19462. Email: TJohnson@nccn.org
  • Collapse
  • Expand
Print ISSN:
1540-1405
Online ISSN:
1540-1413
Publisher:
National Comprehensive Cancer Network
Cover Journal of the National Comprehensive Cancer Network
  • 1.

    Mariotto AB, Enewold L, Zhao J, et al. Medical care costs associated with cancer survivorship in the United States. Cancer Epidemiol Biomarkers Prev 2020;29:1304–1312.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 2.

    American Cancer Society; Cancer Action Network. The Costs of Cancer: 2020 Edition. Accessed July 21, 2021. Available at: www.fightcancer.org/sites/default/files/National%20Documents/Costs-of-Cancer-2020-10222020.pdf

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Ekwueme DU, Zhao J, Rim SH, et al. Annual out-of-pocket expenditures and financial hardship among cancer survivors aged 18–64 years — United States, 2011–2016. MMWR Morb Mortal Wkly Rep 2019;68:494–499.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Elijah E. Cummings Lower Drug Costs Now Act, HR 3, 116th Cong (2019–2020). Accessed July 21, 2021. Available at: https://www.congress.gov/bill/116th-congress/house-bill/3

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Wynne B, Llamas A. New Legislation to Control Drug Prices: How Do House and Senate Bills Compare? The Commonwealth Fund website. Accessed July 21, 2021. Available at: www.commonwealthfund.org/blog/2019/new-legislation-control-drug-prices-how-do-house-and-senate-bills-compare

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Perspectives on the Future of Lowering Costs in the American Healthcare System and Implication’s for the Oncology Community. Panel Discussion at the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care; September 9, 2020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Chambers JD, Lai RC, Margaretos NM, et al. Coverage for biosimilars vs reference products among US commercial health plans. JAMA 2020;323:1972–1973.

  • 8.

    Graetz I. The health IT special issue: enduring barriers to adoption and innovative predictive methods. The Am J Manag Care 2020;26:19.

  • 9.

    Kim J. Challenges to EHR optimization for cancer programs-workload, cost, and interoperability. Association of Community Cancer Centers website. Accessed July 21, 2021. Available at: www.accc-cancer.org/acccbuzz/blog-post-template/accc-buzz/2017/05/30/challenges-to-ehr-optimization-for-cancer-programsworkload-cost-and-interoperability

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Barkley R, Soobader MJ, Wang J, et al. Reducing cancer costs through symptom management and triage pathways. J Oncol Pract 2019;15:e91–97.

  • 11.

    Phillips RL Jr, Bronnikov S, Petterson S, et al. Case study of a primary care-based accountable care system approach to medical home transformation. J Ambul Care Manage 2011;34:67–77.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Branning G, Lynch M, Hayes K. Value-based agreements in healthcare: willingness versus ability. Am Health Drug Benefits 2019;12:232–234.

  • 13.

    Oncology Care Model. CMS.gov. Accessed July 21, 2021. Available at: innovation.cms.gov/innovation-models/oncology-care

  • 14.

    Innovative Reimbursement Models in Medicare and Medicaid. Keynote at the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care; September 9, 2020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    CMS Perspective: Oncology Care Model (OCM) second annual evaluation report and next steps on oncology innovation. July 2020. Accessed July 21, 2021. Available at: innovation.cms.gov/data-and-reports/2020/cms-perspective-ocm

    • PubMed
    • Export Citation
  • 16.

    Evaluation of the Oncology Care Model: Performance Period 1–3 – Appendices. Accessed July 21, 2021. Available at: innovation.cms.gov/data-and-reports/2020/ocm-evaluation-annual-report-2-appendices

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Miller HD. Accelerating value-based payment and supporting patient-centered care through more efficient and effective innovation. Accessed July 21, 2021. Available at: https://www.chqpr.org/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    2018 National Scorecard on Commercial Payment Reform. Catalyst for Payment Reform website. Accessed July 21, 2021. Available at: www.catalyze.org/product/2018-national-scorecard/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Getting Providers and Payers to the Other Side: Best Practices for Succeeding in Commercial Value-Based Agreements. Panel Discussion at the NCCN Policy Summit: Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care; September 9, 2020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Morse S. If only the claims were clean: payers, providers lose big on inaccuracies, poor workflows. Healthcare Finance website. Accessed July 21, 2021. Available at: https://www.healthcarefinancenews.com/news/if-only-claims-were-clean-payers-providers-lose-big-inaccuracies-poor-workflows

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Carlson RW. Treatment barriers create racial disparities in cancer care. They need to come down. Accessed July 21, 2021. Available at: https://www.statnews.com/2020/06/24/cancer-care-racial-disparities-dismantle-barriers/

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    LaVeist TA, Gaskin D, Richard P. Estimating the economic burden of racial health inequalities in the United States. Int J Health Serv 2011;41:231–238.

  • 23.

    Centers for Disease Control and Prevention. Key Updates for Week 2, ending January 16, 2021. Accessed February 1, 2021. Available at: https://www.cdc.gov/coronavirus/2019-ncov/covid-data/covidview/index.html

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 24.

    Access and Equity in the Age of COVID. Keynote at the NCCN Policy Summit. Innovative Solutions to Drive Down Healthcare Costs: Implications for Access to High Quality Cancer Care; September 9, 2020.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    U.S. Food & Drug Administration. 2019 Drug Trials Snapshots: Summary Report. Accessed July 21, 2021. Available at: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots

    • PubMed
    • Search Google Scholar
    • Export Citation
Copyright:
Copyright © 2021 by the National Comprehensive Cancer Network 2021
Page Numbers:
6
Article Category:
Other
Received:
19 Feb 2021
Accepted:
27 Jul 2021
Print Publication Date:
01 Sep 2021
Online Publication Date:
20 Sep 2021

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2634 575 75
PDF Downloads 981 110 10
EPUB Downloads 0 0 0